Journal Logo

January 2021 - Volume 77 - Issue 1

  • George W. Booz, PhD, FAHA
  • 0160-2446
  • 1533-4023
  • 12 issues per year
  • Cardiac & Cardiovascular Systems 62/138, Pharmacology & Pharmacy 147/270
  • 2.598

The January issue has a number of exciting articles that cover a broad swath of cardiovascular pharmacology.  One noteworthy contribution is an Emerging Concepts in Pharmacotherapeutics review article by Drs. Thomas D. Bernier and Leo F. Buckley, entitled Cardiac Myosin Activation for the Treatment of Systolic Heart Failure. Their article discusses at length two novel cardiac myotropes, omecamtiv mecarbil and danicamtiv. These drugs target cardiac myosin to increase left ventricular systolic performance by increasing the number of myosin-actin interactions. Neither affects cardiac myocyte calcium handling, which is thought to contribute to the life-threatening arrhythmias associated with cardiac calcitropes and calcium sensitizers. These agents also have minimal hemodynamic and renal effects.  Phase 2 clinical trials have shown that these cardiac myosin activators prolong left ventricular systolic ejection time and promote left ventricular and atrial reverse remodeling.  An ongoing phase 3 clinical trial, GALACTIC-HF, will determine the potential role of cardiac myosin activation in treating chronic heart failure with reduced ejection fraction. Additional analyses are needed to better understand the basis for myocardial ischemia and impaired diastolic function at higher plasma concentrations in some patients. However, overall, the evidence indicates that these agents offer promise for patients with advanced heart failure refractory to guideline-directed neurohormonal blockers.

Current Issue Highlights

Review Article

Original Article

Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II–III Systolic Heart Failure

Wohlford, George F.; Van Tassell, Benjamin W.; Billingsley, Hayley E.; More

Journal of Cardiovascular Pharmacology. 77(1):49-60, January 2021.

Angiotensin-Converting Enzyme Inhibitor–based Versus Angiotensin Receptor Blocker–based Optimal Medical Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study

Park, Sangwoo; Kim, Yong-Giun; Ann, Soe Hee; More

Journal of Cardiovascular Pharmacology. 77(1):61-68, January 2021.